Tobias was appointed CFO designate of Haleon in December 2021, having been CFO of the division since 2017.
Prior to joining GSK, Tobias was the Chief Financial Officer at Sandoz – Novartis’ Generics Division. In 2010, he was named Chief Financial Officer for the former Novartis Consumer Health Division, a position that evolved into Tobias' role as CFO for the Novartis OTC division. Earlier in his career he held both local and global finance leadership roles at Novartis in the US, Germany and Switzerland, for example as Global Head of Finance for the Animal Health business, Global Controller for Sandoz and CFO for Hexal.
Favourite brand: Voltaren